NCX-4016 NicOx

Current Opinion in Investigational Drugs

Volumn 4, Issue 9, 2003, Pages 1126-1139

  Di Napoli, Mario ^a   Papa, Francesca ^a  

^a SMDN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID 4 NITROXYBUTYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; CASPASE; CELECOXIB; CYCLIC GMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ESTER DERIVATIVE; FERULIC ACID; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; GLYCOPROTEIN P; HYDROCHLORIC ACID; ICOSANOID; LIPOXIN A; METHYLENE BLUE; NCX 2216; NCX 701; NITRIC OXIDE ACETYLSALICYLIC ACID; NITRIC OXIDE SYNTHASE; NITRO DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; NOR 3; OXYHEMOGLOBIN; PLACEBO; THROMBOXANE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHRITIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CANCER; COLON TUMOR; DIABETES MELLITUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DUODENUM DISEASE; ENZYME INHIBITION; GASTRITIS; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HUMAN; HYPERALGESIA; INFLAMMATION; KIDNEY PAPILLA NECROSIS; LIVER CIRRHOSIS; LUNG EMBOLISM; NEPHROTOXICITY; NITRATE UPTAKE; PAIN; PAW EDEMA; PERIPHERAL VASCULAR DISEASE; PHYSICAL CHEMISTRY; RESTENOSIS; REVIEW; STOMACH DISEASE; STOMACH INJURY; STOMACH MUCOSA INJURY; STOMACH ULCER; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; TOXICITY TESTING; ULCER; VEIN DISEASE; WOUND HEALING IMPAIRMENT;

ANIMALS; ASPIRIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; NITRIC OXIDE; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0142245359     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. 190759 A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Elliott SN, McKnight W, Cirino G, Wallace JL Gastroenterology 1995 109 2 524-530
2. 210800 Effects of a new class of NO-releasing NSAIDs on platelets and isolated arteries. Minuz P, Lechi C, Bonapace S, Gaino S, Adami A, Cuzzolin L, Del Soldatoo P, Benoni G Inflammopharmacology 1996 4 1 83-90 Data on the different effects (release of NO and inhibition of cyclooxygenase) of NO-SAIDs in vitro.
3. 2 production in rats. Cuzzolin L, Adami A, Degan M, Crivellente F, Bonapace S, Minuz P, Benoni G Life Sci 1996 58 11 PL207-PL210
4. 220944 A diclofenac derivative without ulcerogenic properties. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G Eur J Pharmacol 1994 257 3 249-255
5. 222690 NicOx' products enter phase I trials. Scrip 1996 2171 11
6. 224276 NO-NSAID: A new class of GI sparing nonsteroidal anti-inflammatory drugs. Cirino G, Del Soldato P, Robinson B, Wallace JL Int Congr Inflamm Res Assoc 1996 8 PA Abs P70
7. 2 production. Lechi C, Andrioli G, Gaino S, Tommasoli R, Zuliani V, Ortolani R, Degan M, Benoni G, Bellavite P, Lechi A, Minuz P Thromb Haemost 1996 76 5 791-798
8. 229298 In vitro study of the anti-aggregating activity of two nitroderivatives of acetylsalicylic acid. Lechi C, Gaino S, Tommasoli R, Zuliani V, Bonapace S, Fontana L, Degan M, Lechi A, Minuz P Blood Coagul Fibrinolysis 1996 7 2 206-209
9. 241218 Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single dose in rats. Tagliaro F, Cuzzolin L, Adami A, Scarcella D, Crivellente F, Benoni G Life Sci 1997 60 2 101-106
10. 255359 Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Minuz P, Lechi C, Tommasoli R, Gaino S, Degan M, Zulianio V, Bonapace S, Benoni G, Adami A, Cuzzolin L et al Thromb Res 1995 80 5 367-376
11. 255361 Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. Wallace JL, McKnight W, Del Soldato P, Baydoun AR, Cirino G J Clin Invest 1995 96 6 2711-2718
12. 255362 Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal-sparing properties. Cirino G, Wheeler Jones CP, Wallace JL, Del Soldato P, Baydoun AR Br J Pharmacol 1996 117 7 1421-1426
13. 275922 NCX-4016. Cirino G, Calignabno A, Sannicolo F, Primavera A, Del Soldato P, Wallace JL Drugs Future 1997 22 11 1231-1233
14. 281704 NicOx to research "nitro-aspirins" with Bayer. Scrip 1998 2317 10
15. 286587 Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: Role of neutrophils. Wallace JL, McKnight W, Wilson TL, Del Soldato P, Cirino G Am J Physiol - Gastrointest Liver Physiol 1997 273 6 Pt 1 G1246-G1251
16. 300376 NicOx signs exclusive licence agreement for NO-NSAIDs with Astra. NicOx SA NicOx SA Press Release 1998 October 02
17. 301741 Selective COX-2 inhibitors: Are they safe for the stomach? Yeomans ND, Cook GA, Giraud AS Gastroenterology 1998 115 1 227-229
18. 308126 Effects of very low doses of aspirin (ASA) on gastric, duodenal and rectal prostaglandins (PGs) and mucosal injury. Cryer B, Luk G, Feldman M Gastroenterology 1995 108 4 Suppl A77
19. 316822 NicOx IPO seeking $80M for nitric oxide treatments. Bioworld International 1999 4 8 1-3
20. 319225 Healthcare Global: Pharma Pipelines - Volume 1 of 2. Lehman Brothers Inc 1999 February
21. 333036 Protectant effect of nitroderivative of aspirin, NCX 4016, against acute myocardial infarct in the rabbit. Rossoni G, Berti M, Benareggi M, Del Soldato P, Berti F Mediators Inflamm 1999 8 Suppl 1 P-11-31
22. 333045 NCX 4016, a nitroderivative of aspirin, protects the isolated rabbit heart from postischemic ventricular disfunction. Rossoni G, Bernareggi M, Del Soldato P, Primavera A, Berti F Mediators Inflamm 1999 8 Suppl 1 P-11-32
23. 339282 The new nitroderivative of aspirin, NCX 4016, displays protectant activity against myocardial infarct in the rabbit. Rossoni G, Berti M, Del Soldato P, Berti F Thromb Haemost 1999 Suppl Abs 2664
24. 351488 Offering Circular: NicOx SA. NicOx SA Company Prospectus 1999 November 02
25. 356476 New oral formulation of NCX-4016 (NO-aspirin) initiates phase I clinical trials in France. NicOx SA Press Release 2000 February 21
26. 370949 Effect of nitric oxide donors and aspirin on prostinoids and inducible nitric oxide synthase in infarcted heart muscle. Yammamoto T, Kahar R, Vina E, Johnson P, Bing RJ FASEB J 2000 4 Abs 112.12
27. 377837 CPT 2000 (Part VIII), Seventh Conference on Clinical Pharmacology and Therapeutics and Fourth Congress of the European Association for Clinical Pharmacology and Therapeutics, Florence, Italy. Archibald K IDDB Meeting Report 2000 July 15-20
28. 383084 NicOx announces National Cancer Institute research grant to study cancer prevention with its NO-releasing chemopreventive agents. NicOx SA Press Release 2000 September 21
29. 388395 BioPartnering - NicOx SA. Ann Biopartnering Europe Meet 2000 October 16-17
30. 390664 NO-aspirin (NCX 4016) effective in preventing vein graft failure in animal models. NicOx SA Press Release 2000 November 21
31. 396119 NicOx: Harnessing the power of nitric oxide. Technology Update: NiCox SA, London UK. Company Presentation 2001 January 16
32. 409357 NO-NSAIDs alter cell kinetics in human colon cancer cell lines more efficiently than traditional NSAIDs. Williams JL, Hasan I, Borgo S, Castillo E, Traganos F, Rigas B Gastroenterology 2001 120 5 Suppl 1 Abs 879
33. 409391 Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. Kato S, Araki H, Komoike Y, Tashima K, Takeuchi K Gastroenterology 2001 120 5 Suppl. 1 Abs 782
34. 414370 NCX4016 (NO-aspirin) inhibits tissue factor expression and cytokine release in stimulated human monocytes. Minuz P, Degan M, Lechi Santonastaso C, Gaino S, Zullani V, Del Soldato P, Lechi A Thromb Haemost 2001 Abs P1620
35. 414620 Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs; Implications for colon cancer chemoprevention. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B Cancer Res 2001 61 8 3285-3289
36. 423601 Inhibition of NF-kB activation by nitro-paracetamol and nitro-apirin in J774 macrophages. Cui Z, Del Soldato P, Moore PK, Baydoun AR Inflamm Res 2001 50 Suppl 3 04/02
37. 425318 NicOx - Unique expertise in nitric oxide drugs. Stratan I, Gregori F BNP/PARIBAS 2001 August 29
38. 429343 Altana to establish Genomics Research Center in the US. Byk Gulden Press Release 2001 November 13
39. 448027 Positive phase I/IIa clinical results for nitric oxide-donating aspirin showing novel inhibition of vascular inflammation and platelet activation. NicOx SA Press Release 2002 April 16
40. 449771 Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Rossoni G, Muscara MN, Cirino G, Wallace JL Br J Pharmacol 2002 135 6 1540-1546
41. 449775 Colon cancer prevention with NO-releasing NSAIDs. Kaza CS, Kashfi K, Rigas B Prostaglandins 2002 67 2 107-120
42. 449780 Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: An overview. Ignarro LJ, Napoli C, Loscalzo J Circ Res 2002 90 1 21-28
43. 449782 Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Ignarro LJ, Buga GM, Wei LH, Bauer PM, Wu G, Del Soldato P Proc Natl Acad Sci USA 2001 98 7 4202-4208
44. 449783 Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, Pinto A, Ignarro LJ Proc Natl Acad Sci USA 2001 98 5 2860-2864
45. 449785 Low gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in rats with cirrhosis and arthritis. Kato S, Suzuki K, Ukawa H, Komoike Y, Takeuchi K Dig Dis Sci 2001 46 8 1690-1699
46. 449787 Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Muscara MN, Lovren F, McKnight W, Dicay M, Del Soldato P, Triggle CR, Wallace JL Br J Pharmacol 2001 133 8 1314-1322
47. 449790 NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes. Minuz P, Degan M, Gaino S, Meneguzzi A, Zuliani V, Santonastaso CL, Soldato PD, Lechi A Br J Pharmacol 2001 134 4 905-911
48. 449794 NCX4016 (NO-aspirin) inhibits thromboxane biosynthesis and tissue factor expression and activity in human monocytes. Minuz P, Degan M, Gaino S, Meneguzzi A, Zuliani V, Lechi Santonastaso C, Del Soldato P, Lechi A Med Sciences Monitor 2001 7 4 573-577
49. 449797 Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: In vitro and in vivo studies in the rat by ESR spectroscopy. Carini M, Aldini G, Stefani R, Orioli M, Facino RM J Pharm Biomed Anal 2001 26 4 509-518
50. 449801 The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat. Rossoni G, Manfredi B, Colonna VD, Bernareggi M, Berti F J Pharmacol Exp Ther 2001 297 1 380-387
51. 449802 Nitric oxide: An emerging role in cardioprotection? Rakhit RD, Marber MS Heart 2001 86 4 368-372
52. 449803 Regression of early events of atherosclerosis in hypercholesterolemic rabbits by prophylactic treatment with nitroderivative of acetyl salicylic acid. Gad MZ, Khattab MM, Moustafa NA, Burgaud JL Drug Dev Res 2001 53 4 237-243
53. 449804 NO-releasing NSAIDs are caspase inhibitors. Fiorucci S Trends Immunol 2001 22 5 232-235
54. 449805 Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. Fredduzzi S, Mariucci G, Tantucci M, Del Soldato P, Ambrosini MV Neurosci Lett 2001 302 2-3 121-124 This paper describes the first evaluation of a possible neuroprotective effect in a permanent model of cerebral ischemia in rats.
55. 449808 Gastrointestinal sparing anti-inflammatory drugs - Effects on ulcerogenic and healing responses. Takeuchi K, Tanaka A, Suzuki K, Mizoguchi H Curr Pharm Design 2001 7 1 49-69
56. 449814 IL-1β converting enzyme is a target for nitric oxide-releasing aspirin: New insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. Fiorucci S, Santucci L, Cirino G, Mencarelli A, Familiari L, Soldato PD, Morelli A J Immunol 2000 165 9 5245-5254 This paper provides an analysis of the effects of NCX-4016 on cytokine and easpase systems in vitro.
57. 449815 Lack of gastric toxicity of nitric oxide-releasing aspirin, NCX-4016, in the stomach of diabetic rats. Tashima K, Fujita A, Umeda M, Takeuchi K 2000 67 13 1639-1652
58. 449820 The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. Yamamoto T, Kakar NR, Vina ER, Johnson PE, Bing RJ Life Sci 2000 67 7 839-846
59. 449891 A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin. Al Swayeho A, Clifford RH, Del Soldato P, Moore PK Br J Pharmacol 2000 129 2 343-350 This paper provides an accurate analysis of the anti-inflammatory and analgesic properties of NCX-4016. This is a typical pharmacological study in well-established and reproducible models.
60. 449897 Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P, Page CP, Gresele P Eur J Pharmacol 2000 397 1 177-185
61. 449901 Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B, Mannucci R, Del Soldato P, Morelli A Gastroenterology 1999 116 5 1089-1106
62. 449904 Nitric oxide-releasing NSAIDs inhibit interleukin-1β converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFα. Fiorucci S, Santucci L, Federici B, Antonelli E, Distrutti E, Morelli O, Renzo GD, Coata G, Cirino G, Del Soldato P, Morelli A Aliment Pharmacol Ther 1999 13 3 421-435
63. 449907 NO-aspirins: A class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 1999 20 8 319-323
64. 449911 In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Wallace JL, Muscra MN, McKnight W, Dicay M, Del Soldato P, Cirino G Thromb Res 1999 93 1 43-50 This paper provide a complete analysis of hte pharmacological properties of NCX-4016. Data on gastric sparing, PG inhibition, antithrombotic properties, NO release and pharmacokinetics are presented.
65. 449913 Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses. Takeuchi K, Suzuki K, Yamamoto H, Araki H, Mizoguchi H, Ukawa H J Physiol Pharmacol 1998 49 4 501-513
66. 449914 Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: Comparison with plain aspirin. Takeuchi K, Ukawa H, Konaka A, Kitamura M, Sugawa Y J Pharmacol Exp Ther 1998 286 1 115-121
67. 449916 NO-aspirins: Antithrombotic activity of derivatives of acetyl salicylic acid releasing nitric oxide. Minuz P, Lechi C, Zuliani V, Gaino S, Tommasoli R, Lechi A Cardiovasc Drug Rev 1998 16 1 31-47
68. 450025 Nitric oxide prevents mucosal damage induced by NSAIDs in H. pylori infection. Hiroto M, Oka H, Shiotani A, Iguchi M, Shinngaki N, Inoue I, Maekita T, Yanaoka K, Arii K, Ichinose M Gastroenterology 2001 120 5 Suppl 1 A147
69. 450026 COX-2 selective inhibitors cause gastric damage in aspirin treated rats. Protective effect of nitroaspirin (NCX-4016). Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Distrutti E, Morelli A Gastroenterology 2001 120 5 Suppl 1 A595
70. 450029 NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Fiorucci S, Santucci L, Antonelli E, Distrutti E, Del Sero G, Morelli O, Romani L, Federici B, Del Soldato P, Morelli A Gastroenterology 2000 118 2 404-421
71. 450050 Chemoprevention of colonic adenocarcinoma in the rat with an aspirin derivative: Lack of a role for cyclooxygenase inhibition. Bak AW, McKnight W, Li P, Del Soldato P, Wallace JL Gastroenterology 1998 114 4 Part 2 A562
72. 450051 Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, Wallace JL Life Sci 1998 62 23 367-373
73. 450062 Myocardial protection by the nitroderivative of aspirin, NCX 4016: In vitro and in vivo experiments in the rabbit. Rossini G, Berti M, Colonna VD, Bernareggi M, Del Soldato P, Berti F Ital Heart J 2000 1 2 146-155
74. 451465 Risk of cardiovascular events associated with selective COX-2 inhibitors. Mukherjee D, Nissen SE, Topol EJ J Am Med Assoc 2001 286 8 954-959
75. 451868 Intraperitoneal NO-aspirin (NCX-4016) administration reverses pain induced by colorectal distension. Modulation COX-2 and iNOS in the spinal cord. Eleonora D, Francis SN, Susanne HK, Mario R, Vincenzo B, Barabara P, Barabara F, Antonio M, Piero DS, Antonio M, Stefano F Gastroenterology 2002 122 4 Suppl 1 Abs W1033
76. 454485 Bio 2002 - International Biotechnology Convention and Exhibition (Part V) - Overnight Report, Toronto, Canada. McGowran M IDDB Meeting Report 2002 June 9-12
77. 455654 Effect of insulin on vascular responses mediated by adrenergic and CGRPergic nerves in pithed rats. Takatori S, Mizote M, Kurosaki Y, Kawasaki H, World Congr Pharmacol 2002 24 July 7-12 Abs 95.1
78. 457376 World Congress of Pharmacology - XIVth Annual Meeting (Part II) - Overnight Report, San Francisco, CA, USA. Durrance A IDDB Meeting Report 2002 July 7-12
79. 457636 World Congress of Pharmacology - XIVth Annual Meeting (Part V) - Overnight Report, San Francisco, CA, USA. Waterworth C IDDB Meeting Report 2002 July 7-12
80. 467771 NicOx granted US IND for phase II trials with NCX 4016 in cardiovascular diseases. NicOx SA Press Release 2002 October 24
81. 471244 NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Zoli W, Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D AACR NCI EORTC Mol Targets Cancer Ther 2002 13 Abs 276
82. 471413 Nitric oxide-releasing drugs: A novel class of effective and safe therapeutic agents. Burgaud J L, Ongini E, Del Soldato P Ann NY Acad Sci 2002 962 Abs 360-Abs 371
83. 471417 Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Napoli C, Achah E, De Nigris F, Del Soldato P, D'Armiento FP, Crimi E, Condorelli M, Sessa WC Proc Natl Acad Sci USA 2002 99 19 12467-12470
84. 471418 NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. Wainwright CL, Miller AM, Work LM, Del Soldato P Br J Pharmacol 2002 135 8 1882-1888
85. 471439 In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. Carini M, Aldini G, Orioli M, Maffei Facino R J Pharm Biomed Anal 2002 29 6 1061-1071 This is an interesting paper describing the in vitro metabolism of NCX-4016 in rat liver; The metabolic pathway is described. This is very accurate from a methodological point of view.
86. 471488 Nitric-oxide releasing molecules: A new class of drugs with several major indications. Burgaud JL, Riffaud JP, Del Soldato P Curr Pharm Design 2002 8 3 201-213
87. 480468 NicOx reports year-end 2002 financial results. NicOx SA Press Release 2003 March 03
88. 481084 A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, Stern S, Quan H, Bolognese J Gastroenterology 1999 117 4 776-783
89. 481794 NicOx announces National Cancer Institute Grant for a human clinical trial of NCX 4016 in prevention of colon cancer. NicOx SA Press Release 2003 March 13
90. 490457 Clinical results show NicOx's NCX 4016 maintains excellent gastric safety in co-administration with celecoxib. NicOx SA Press Release 2003 May 21
91. 490490 Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Wallace JL, Mencarelli A, Del Soldato P, Fiorucci S Gastroenterology 2003 124 4 Suppl 1 105275 Abs 719
92. 490495 Celecoxib exacerbates gastrointestinal damage induced by aspirin but not by NO-aspirin (NCX-4016). Fiorucci S, Santucci L, Mencarelli A, Distrutti E, Fanini C, Federici B, Sardina M, Santus G, Wallace JW, Del Soldato P, Morelli A Gastroenterology 2003 124 Suppl 1 106313 Abs 722
93. 490540 Ulcer healing in diabetic rats treated with aspirin, nitric oxide (NO)-derivative of aspirin and COX-2 inhibitor. Brzozowski T, Konturek PC, Sliwowski Z, Pawlik M, Stachura J, Konturek SJ, Jaworek J, Pawlik WW, Hahn EG Gastroenterology 2003 124 Suppl 1 S1196
94. 490832 Digestive Disease Week 2003 (Part IV), Orlando, FL, USA. Gotham S IDDB Meeting Report 2003 May 17-22
95. 494481 Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Wolfe NM, Lichtenstein DR, Singh G N Engl J Med 1999 340 24 1888-1899
96. 494548 Aspirin as an antiplatelet drug. Patrono C N Engl J Med 1994 330 18 1287-1294
97. 494600 Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991 338 8779 1345-1349
98. 494602 Extracranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC Thromb Haemost 1992 68 1 1-6
99. 494608 Cyclooxygenase-2: Pharmacology, physiology, biochemistry and relevance to NSAID therapy. Mitchell JA, Warner TD Br J Pharmacol 1999 128 6 1121-1132
100. 494615 Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. McAdam BF, Catella Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA Proc Natl Acad Sci USA 1999 96 1 272-277
101. 494616 Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Crofford LT, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella Lawson F, Morrow JD, McDonagh KT, Schmaier AH Arthritis Rheum 2000 43 8 1891-1896
102. 494633 Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP et al Ann Intern Med 2000 133 1 1-9
103. 494634 Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Rossat J, Maillard M, Nussberger J, Brunner HR, Brunier M Clin Pharmacol Ther 1999 66 1 76-84
104. 494636 Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Muscara MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL Br J Pharmacol 2000 129 7 1423-1430
105. 494637 Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkley KA, MacNaughton WK Gastroenterology 1998 115 1 101-109
106. 494638 Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: Novel gastrointestinal-sparing drugs. Bandarage UK, Janero DR Mini Rev Med Chem 2001 1 1 57-70 This paper provides an accurate and update description of the chemical, biochemical and pharmacological properties of nitric oxide-releasing molecules. Both nitroxylbutyl ester and nitrosothiol NSAID derivatives are described.
107. 494639 The cellular and molecular basis of gastric mucosal defense. Wallace JL, Granger DN FASEB J 1996 10 7 731-740
108. 494641 Nitric oxide releasing NSAIDs: GI-safe antithrombotics. Wallace JL, Del Soldato P, Cirino G, Muscara MN IDrugs 1999 2 4 321-326
109. 494644 Nitric oxide-releasing drugs: A novel class of effective and safe therapeutic agents. Burgaud JL, Ongini E, Del Soldato P Ann NY Acad Sci 2002 962 360-371
110. 494647 Plasma concentrations and pharmacokinetic parameters of nitrofenac using a simple and sensitive HPLC method. Benoni G, Terzi M, Adami A, Grigolini L, Del Soldato P, Cuzzolin L J Pharm Sci 1995 84 1 93-95
111. 494648 Potential cardioprotective actions of NO-releasing aspirin. Wallace JL, Ignarro LJ, Fiorucci S Nat Rev Drug Disc 2002 1 5 375-382
112. 494649 NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. Fiorucci S, Mencarelli A, Mannucci R, Distrutti E, Morelli A, Morelli P, Moncada S FASEB J 2002 16 12 1645-1647 An interesting and suggestive mechanism of action is proposed in this paper to explain the anti-apoptotic effect of NCX-4016.
113. 494650 Gastric irritancy of aspirin and its congeners: Antiinflammatory activity without this side-effect. Rainsford KD, Whitehouse MW J Pharm Pharmacol 1976 28 7 599-601
114. 494651 Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. Cena C, Lolli ML, Lazzarato K, Guaita E, Morini G, Coruzzi G, McElroy SP, Megson IL, Fruttero R, Gasco A J Med Chem 2003 46 5 747-754 A new series of NO-aspirin is described in this paper, in which aspirin is joined by an ester linkage to furoxan moieties. This series has a different ability to release NO compared with NCX-4016.
115. 494652 Nitric oxide releasing aspirin protects the gastric mucosa against stress and promotes healing of stress-induced gastric mucosal damage: Role of heat shock protein 70. Konturek PC, Brzozowski T, Ptak A, Kania J, Kwiecien S, Hahn EG, Konturek SJ Digestion 2002 66 3 160-172
116. 494653 NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: Role of nitric oxide. Fiorucci S, Mencarelli A, Meneguzzi A, Lechi A, Morelli A, Del Soldato P, Minuz P Circulation 2002 106 24 3120-3125
117. 494654 Vascular protective actions of a nitric oxide aspirin analog in both in vitro and in vivo models of diabetes mellitus. Pieper GM, Siebeneich W, Olds CL, Felix CC, Del Soldato P Free Radic Biol Med 2002 32 11 1143-1156 This well-written paper demonstrates a significant antioxidant effect of NCX-4016 both in vitro and in vivo, which modifies the natural history of vascular endothelium impairment in a rat model of diabetes mellitus. An innovative methodology based on electron paramagnetic resonance with spin trapping is used.
118. 494654 Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Yu J, Rudic RD, Sessa WC Lab Invest 2002 82 7 825-832
119. 494665 NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W Int J Oncol 2003 22 6 1297-1302 This paper describes the cytostatic and cytocidal effects of NCX-4016.
120. 494672 Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. Kashfi K, Ryann Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B J Pharmacol Exp Ther 2002 303 3 1273-1282
121. 494673 The therapeutic potential of NO-NSAIDs. Wallace JL, Del Soldato P Fundam Clin Pharmacol 2003 17 1 11-20
122. 494674 A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity. Handy RL, Moore PK Br J Pharmacol 1998 123 6 1119-1126
123. 494676 Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Maricic N, Ehrlich K, Gretzer B, Schluligoi R, Respondek M, Peskar BM Br J Pharmacol 1999 128 8 1959-1666
124. 494680 Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Whelton A Am J Med 1999 106 5B 13S-24S
125. 494686 Nonsteroidal anti-inflammatory drugs and antihypertensives. Houston MC Am J Med 1991 90 5A 42S-47S
126. 494688 Vasorelaxant effect of nitric oxide releasing steroidal and nonsteroidal anti-inflammatory drugs. Keeble J, Al-Swayeh OA, Moore PK Br J Pharmacol 2001 133 7 1023-1028
127. 494691 Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: A proof of concept endoscopic study. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A Gastroenterology 2003 124 3 600-607
128. 494692 New look at myocardial infarction: Toward a better aspirin. Bing RJ, Yamamoto T, Yamamoto M, Kakar R, Cohen A Cardiovasc Res 1999 43 1 25-31
129. 496694 Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. Insel PA Pharmacol Basis Ther 9th Edition. Eds Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Pergamon Press, New York, NY, USA 1996 9 617-657
130. 496696 Food and Drug Administration Arthritis Advisory Committee meeting on Vioxx, April 20, 1999. The FDA Internet Site 1999 April 20
131. 496699 Food and Drug Administration Arthritis Advisory Committee meeting on Celebrex, December 1, 1998. The FDA Internet Site 1998 December 01
132. 497185 Drug-induced ulcerogenesis. Agrawal NM, Dajani EZ Gastrointestinal Pharmacol Ther Eds: Friedman J, Jacobson E, McCallum R, Lippincott Raven, Philadelphia, PA, USA 1997 55-63
133. 499472 Clinical pipeline: NCX-4016. NicOX SA Company World Wide Web Site 2003 June 19